Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-09-14 4:34 pm Sale | 2022-09-12 | 13D | SpringWorks Therapeutics, Inc. SWTX | ORBIMED ADVISORS LLC | 5,599,842 9.300% | -586,465 (-9.48%) | Filing History |
| 2022-08-30 4:37 pm Purchase | 2022-08-26 | 13D | Xtant Medical Holdings, Inc. XTNT | ORBIMED ADVISORS LLC | 73,114,592 67.900% | 241,098 (+0.33%) | Filing History |
| 2022-08-26 4:12 pm Sale | 2022-08-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 2,828,356 4.700% | -318,368 (-10.12%) | Filing History |
| 2022-08-19 4:17 pm Unchanged | 2022-08-18 | 13D | TELA Bio, Inc. TELA | ORBIMED ADVISORS LLC | 3,058,267 16.500% | 0 (Unchanged) | Filing History |
| 2022-08-18 4:39 pm Purchase | 2022-08-16 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 7,481,204 19.900% | 3,690,000 (+97.33%) | Filing History |
| 2022-08-12 2:29 pm Purchase | 2022-08-10 | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 5,028,174 6.900% | 5,028,174 (New Position) | Filing History |
| 2022-08-08 4:26 pm Sale | 2022-08-04 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 3,146,724 5.400% | -387,813 (-10.97%) | Filing History |
| 2022-07-05 4:30 pm Sale | 2022-07-05 | 13D | 89bio, Inc. ETNB | ORBIMED ADVISORS LLC | 1,829,436 4.700% | -35,285 (-1.89%) | Filing History |
| 2022-06-28 4:22 pm Sale | 2022-06-24 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 3,534,537 6.900% | -306,027 (-7.97%) | Filing History |
| 2022-05-05 4:56 pm Purchase | 2022-05-03 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 342,071 12.600% | 44,705 (+15.03%) | Filing History |
| 2022-04-08 5:20 pm Sale | 2022-04-06 | 13D | Arcutis Biotherapeutics, Inc. ARQT | ORBIMED ADVISORS LLC | 3,840,564 7.600% | -427,000 (-10.01%) | Filing History |
| 2022-04-01 5:06 pm Unchanged | 2022-03-29 | 13D | PMV Pharmaceuticals, Inc. PMVP | ORBIMED ADVISORS LLC | 6,589,330 14.500% | 0 (Unchanged) | Filing History |
| 2022-03-15 4:30 pm Unchanged | 2022-03-10 | 13D | Sierra Oncology, Inc. SRRA | ORBIMED ADVISORS LLC | 3,044,753 12.200% | 0 (Unchanged) | Filing History |
| 2022-02-11 5:09 pm Sale | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | ORBIMED ADVISORS LLC | 631,000 1.220% | -1,080,305 (-63.13%) | Filing History |
| 2022-02-11 5:08 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 61,212 6.400% | 12 (+0.02%) | Filing History |
| 2022-02-11 4:58 pm Purchase | 2021-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | ORBIMED ADVISORS LLC | 350,641 5.300% | 24,681 (+7.57%) | Filing History |
| 2022-02-11 4:57 pm Unchanged | 2021-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA | ORBIMED ADVISORS LLC | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-02-11 4:51 pm Purchase | 2021-12-31 | 13G | VectivBio Holding AG VECT | ORBIMED ADVISORS LLC | 4,903,504 14.000% | 73,500 (+1.52%) | Filing History |
| 2022-02-11 4:49 pm Sale | 2021-12-31 | 13G | Theravance Biopharma, Inc. TBPH | ORBIMED ADVISORS LLC | 5,456,780 7.400% | -87,432 (-1.58%) | Filing History |
| 2022-02-11 4:48 pm Sale | 2021-12-31 | 13G | Strongbridge Biopharma plc SBBP | ORBIMED ADVISORS LLC | 0 0.000% | -2,986,869 (Position Closed) | Filing History |